NCT00925743View on ClinicalTrials.gov

A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Solid Cancer
Interventions
DRUG

cabazitaxel (XRP6258)

"* administered by IV infusion~* in addition to cisplatin treatment"

Trial Locations (7)

21201

Investigational Site Number 840002, Baltimore

62526

Investigational Site Number 840010, Decatur

63110

Investigational Site Number 840006, St Louis

78229

Investigational Site Number 840005, San Antonio

90048

Investigational Site Number 840008, Los Angeles

92123

Investigational Site Number 840003, San Diego

45267-0542

Investigational Site Number 840007, Cincinnati

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00925743 - A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer | Biotech Hunter | Biotech Hunter